Clinical outcomes of nephron sparing surgery for T1 renal cell carcinoma.
- Author:
Pei DONG
1
;
Zhi-Ling ZHANG
;
Guo-Liang HOU
;
Kai YAO
;
Zhuo-Wei LIU
;
Hui HAN
;
Zi-Ke QIN
;
Fang-Jian ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Renal Cell; surgery; Female; Follow-Up Studies; Humans; Kidney Neoplasms; surgery; Male; Middle Aged; Retrospective Studies; Treatment Outcome
- From: Chinese Journal of Surgery 2011;49(1):83-86
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the safety and effect of nephron-sparing surgery (NSS) in treatment of T1a and T1b renal cell carcinoma.
METHODSRetrospective analyzed the clinical data of 101 patients with T1 renal cell carcinoma underwent NSS from November 1999 to December 2009.Including 79 male and 22 female with the mean age of 52.3 years (ranged 28 to 79 years). Based on tumor pathologic diameter, 101 patients were divided into T1a group with 62 patient and T1b group with 39 cases. Demographic, intraoperative, postoperative and follow-up data were compared between the 2 groups.
RESULTSThe operation were performed successfully in all the 101 cases. The mean operation time was (151 ± 80) min in group T1a and (158 ± 50) min in group T1b with no statistical difference (P = 0.32). The mean blood loss was (322 ± 596) ml in group T1a and (308 ± 239) ml in group T1b (P = 0.45). Postoperative follow-up ranged from 8 to 102 months with a mean of 38.4 months. One patient in T1b group died of distant metastasis 36 months after operation. Others were no tumor recurred.
CONCLUSIONNephron-sparing surgery is safe and effective for the treatment of T1a and T1b renal cell carcinoma.
